| Josephine Miriam Harter, MD | |
|
600 Highland Ave, Madison, WI 53792 | |
| (608) 263-8437 | |
| (608) 262-7174 |
| Full Name | Josephine Miriam Harter |
|---|---|
| Gender | Female |
| Speciality | Pathology |
| Experience | 30 Years |
| Location | 600 Highland Ave, Madison, Wisconsin |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1730140252 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZC0500X | Pathology - Cytopathology | 43993 (Wisconsin) | Secondary |
| 207ZP0105X | Pathology - Clinical Pathology/laboratory Medicine | 43993 (Wisconsin) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Wi Hospitals & Clinics Authority | Madison, WI | Hospital |
| Meriter Hospital | Madison, WI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Of Wisconsin Medical Foundation Inc | 6608785464 | 2164 |
News Archive
iWatch News reports on how this finding is raising concern among state officials about how they will keep paying for these systems when the federal money is gone. Meanwhile, KHN -; in partnership with NPR and Oregon Public Radio -; takes a look at how electronic medical records can be used.
X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 antagonists to improve immune cell trafficking to treat cancer and rare disease, today announced results from a pilot study of X4P-001-IO in combination with Opdivo (nivolumab) in patients with clear cell renal cell carcinoma who are non-responsive to the anti-PD-1 checkpoint inhibitor Opdivo alone.
Current strategies for jaw reconstruction require multiple procedures, first to repair the bone defect to offer sufficient support, and then to place the tooth implant.
Today, GE Healthcare Medical Diagnostics announced results of a study that evaluated the cardiopulmonary safety of Optison- (Perflutren Protein-Type A Microspheres Injectable Suspension, USP), a diagnostic ultrasound contrast agent for use in improving suboptimal echocardiograms.
› Verified 1 days ago
| Entity Name | University Of Wisconsin Medical Foundation Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598784555 PECOS PAC ID: 6608785464 Enrollment ID: O20031111000435 |
News Archive
iWatch News reports on how this finding is raising concern among state officials about how they will keep paying for these systems when the federal money is gone. Meanwhile, KHN -; in partnership with NPR and Oregon Public Radio -; takes a look at how electronic medical records can be used.
X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 antagonists to improve immune cell trafficking to treat cancer and rare disease, today announced results from a pilot study of X4P-001-IO in combination with Opdivo (nivolumab) in patients with clear cell renal cell carcinoma who are non-responsive to the anti-PD-1 checkpoint inhibitor Opdivo alone.
Current strategies for jaw reconstruction require multiple procedures, first to repair the bone defect to offer sufficient support, and then to place the tooth implant.
Today, GE Healthcare Medical Diagnostics announced results of a study that evaluated the cardiopulmonary safety of Optison- (Perflutren Protein-Type A Microspheres Injectable Suspension, USP), a diagnostic ultrasound contrast agent for use in improving suboptimal echocardiograms.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Josephine Miriam Harter, MD 7974 Uw Health Ct, Middleton, WI 53562-5531 Ph: () - | Josephine Miriam Harter, MD 600 Highland Ave, Madison, WI 53792 Ph: (608) 263-8437 |
News Archive
iWatch News reports on how this finding is raising concern among state officials about how they will keep paying for these systems when the federal money is gone. Meanwhile, KHN -; in partnership with NPR and Oregon Public Radio -; takes a look at how electronic medical records can be used.
X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 antagonists to improve immune cell trafficking to treat cancer and rare disease, today announced results from a pilot study of X4P-001-IO in combination with Opdivo (nivolumab) in patients with clear cell renal cell carcinoma who are non-responsive to the anti-PD-1 checkpoint inhibitor Opdivo alone.
Current strategies for jaw reconstruction require multiple procedures, first to repair the bone defect to offer sufficient support, and then to place the tooth implant.
Today, GE Healthcare Medical Diagnostics announced results of a study that evaluated the cardiopulmonary safety of Optison- (Perflutren Protein-Type A Microspheres Injectable Suspension, USP), a diagnostic ultrasound contrast agent for use in improving suboptimal echocardiograms.
› Verified 1 days ago
Megan Fitzpatrick, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 3617 Odana Rd, Madison, WI 53711 Phone: 575-770-2064 | |
Lixia Bai, MD, PH.D Pathology Medicare: Medicare Enrolled Practice Location: 600 Highland Ave, Madison, WI 53792 Phone: 608-263-6400 | |
Deborah Turski, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 707 S Mills St, Madison, WI 53715 Phone: 608-251-6100 Fax: 608-826-2710 | |
Dr. Kristina Ann Matkowskyj, MD, PHD Pathology Medicare: Accepting Medicare Assignments Practice Location: 600 Highland Ave, Madison, WI 53792 Phone: 608-263-8443 Fax: 608-262-7174 | |
Yang Zong, Pathology Medicare: Medicare Enrolled Practice Location: 600 Highland Ave, Madison, WI 53792 Phone: 608-263-8443 | |
Ricardo V Lloyd, M.D. Pathology Medicare: Medicare Enrolled Practice Location: 600 Highland Ave, Madison, WI 53792 Phone: 608-263-8443 | |
Chen Kang Chang, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 707 S Mills St, Madison, WI 53715 Phone: 608-251-6100 Fax: 608-826-2710 |